Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jun 01, 2023 11:28am
135 Views
Post# 35474932

RE:RE:RE:RE:RE:RE:RE:Light at the end of the Tunnel

RE:RE:RE:RE:RE:RE:RE:Light at the end of the Tunnel Another one of treeboy's misleading posts.

He just parrots the off-repeated standard "reverse splits never work out" without analyzing the facts of the situation.


The issue is exactly the worth of CTSO compared to that of EDT....

....which is highly likely to be a function of where it trades (ie. mostly the US for CTSO) and promotional efforts.  How else can a Company with very similar products trade at twice the price, when it hasn't even started a Phase 1 Trial?

Most reverse split situations do not involve this particular set of facts (including CTSO's RS).   i.e a RS to save a declining company with a declining SP is never good.  However we are talking about a RS executed in order to up-list, and attract more eyeballs (i.e potential buyers of the stock).

Reverse splits that are done in order to satisfy a minimum $ value for US regulatory purposes, bring with it 25 times the potential demand for the stock.

Price is always a function of supply vs. demand.


Missing from the discussion perhaps?   Maybe someone, or some entity, prefers this off-the-radar stance?

MM


<< Previous
Bullboard Posts
Next >>